Bruce Samuels, MD
Cardiovascular Disease · Beverly Hills, CANPI 1083686372
Payments from drug & device makers
Across 1,781 payments — averaging $335.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$443K
- Philips North America LLC$103K
- Cathworks, Inc.$33K
- Medtronic$6K
- Shockwave Medical, Inc$6K
- Genentech, Inc.$3K
- plus $4K from 30 others
What the payments were for
- Consulting fees$348,72558%
- Speaking & faculty fees$116,88220%
- Travel & lodging$71,58212%
- Food & beverage$57,60110%
- Education$3,0011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 1,218 | $442,834 |
| Philips North America LLC | 274 | $102,908 |
| Cathworks, Inc. | 55 | $32,801 |
| Medtronic | 5 | $6,450 |
| Shockwave Medical, Inc | 115 | $5,510 |
| Genentech, Inc. | 1 | $3,250 |
| Abiomed | 24 | $1,107 |
| Edwards Lifesciences | 9 | $417 |
| Cardiva Medical, Inc. | 5 | $395 |
| Biotronik Inc. | 7 | $343 |
| Amgen | 10 | $249 |
| Acist Medical Systems, Inc. | 3 | $221 |
| Pfizer | 8 | $184 |
| Boston Scientific | 7 | $170 |
| Siemens Medical Solutions USA, Inc. | 1 | $127 |
| Novartis | 5 | $107 |
| E.r. Squibb & Sons, L.L.C. | 6 | $106 |
| Lilly USA, LLC | 3 | $68 |
| Merck | 2 | $49 |
| Johnson & Johnson | 2 | $46 |
| Alnylam Pharmaceuticals Inc. | 2 | $45 |
| Kowa Pharmaceuticals America, Inc. | 1 | $45 |
| Cardiovascular Systems Inc. | 4 | $44 |
| Boehringer Ingelheim | 2 | $40 |
| Recor Medical Inc | 1 | $34 |
| Lexicon Pharmaceuticals, Inc. | 1 | $32 |
| Novo Nordisk | 1 | $27 |
| Shield Therapeutics Inc | 1 | $26 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $24 |
| Getinge USA Sales, LLC | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COROFLOW$139,479
- Xience V coronary stent system$87,602
- (9520) IGT Devices Undivided$74,092
- Dragonfly OCT$54,091
- FFRangio System$31,940
- OPTIS$25,308
- PRESSUREWIRE$21,913
- XIENCE SKYPOINT$21,000
- HI-TORQUE BALANCE$19,250
- MitraClip$15,000
- DRAGONFLY OPSTAR$12,414
- SUPERA$10,004
- Spectranetics Undiv$8,000
- RESOLUTE ONYX$6,283
- XIENCE SIERRA$3,583
- TNKase$3,250
- US Und$3,103
- (792) Multi Modality IVUS Other Systems$3,000
- Omnilink Elite vascular stent system$2,846
- (6361) Core Mobile$2,500
How this compares
$597,791 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 87 | $91,190 |
| EntrestoSacubitril/Valsartan | 34 | $40,375 |
| FarxigaDapagliflozin Propanediol | 38 | $30,652 |
| EliquisApixaban | 32 | $24,898 |
| DapagliflozinDapagliflozin Propanediol | 13 | $6,845 |
| LivaloPitavastatin Calcium | 12 | $4,769 |
| EdarbiAzilsartan Medoxomil | 13 | $3,301 |
| Metoprolol Succinate | 125 | $1,761 |
| Atorvastatin Calcium | 140 | $1,398 |
| Losartan Potassium | 113 | $1,375 |
| Amlodipine Besylate | 131 | $1,039 |
| Ezetimibe | 39 | $1,037 |
| Rosuvastatin Calcium | 71 | $1,018 |
| Olmesartan Medoxomil | 34 | $972 |
| Nebivolol Hcl | 39 | $739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $107 | $40,37534 claims |
| PfizerEliquis | $184 | $24,89832 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $45 | $4,76912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Beverly Hills
- Andriana NikolovaBeverly Hills$980K
- Ronald KarlsbergBeverly Hills$883K
- Charles SwerdlowBeverly Hills$562K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.